Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

(2020) Milton Packer   DIABETES CARE

Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

(2020) Javed Butler et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

(2020) Mark C. Petrie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impaired fasting glucose and development of chronic kidney disease in non-diabetic population: a Mendelian randomization study

(2020) Hyoungnae Kim et al.   BMJ Open Diabetes Research & Care

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events

(2019) Naveen Rathi et al.   AMERICAN JOURNAL OF HYPERTENSION

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

(2019) Milton Packer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients

(2019) Chen Die Yang et al.   Cardiovascular Diabetology

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

(2016) Søren L. Kristensen et al.   Circulation-Heart Failure

Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices

(2010) Nir Uriel et al.   EUROPEAN JOURNAL OF HEART FAILURE

Insulin-Resistant Cardiomyopathy

(2008) Ronald M. Witteles et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY